Literature DB >> 7011986

Pathogenicity of Candida tropicalis and Candida albicans after gastrointestinal inoculation in mice.

J R Wingard, J D Dick, W G Merz, G R Sandford, R Saral, W H Burns.   

Abstract

The ability of clinical isolates of Candida albicans and candida tropicalis to invade through normal and damaged gastrointestinal mucosa was determined. Adult mice were treated with either gentamicin or gentamicin and cytarabine. Suspensions of yeast cells (10(7)) were administered through a catheter intraesophageally. Invasion was determined by culturing liver, kidney, and lung tissue from mice sacrificed after 48 h. C. albicans and C. tropicalis were incapable of invading through normal gastrointestinal mucosa in mice treated only with gentamicin. Two isolates of C. tropicalis penetrated the damaged gastrointestinal mucosa in 69% (49 of 71) of mice treated with gentamicin and cytarabine. In contrast, three isolates of C. albicans penetrated he damaged gastrointestinal mucosa in only 23% (14 of 62) of mice. These results suggest that C. tropicalis is more capable of invading through damaged gastrointestinal mucosa than C. albicans. The observations in this mouse model parallel those seen in patients on cytotoxic drugs. Therefore, this model offers a tool for investigation of the pathogenicity of these organisms in a model analogous to the compromised host.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7011986      PMCID: PMC551194          DOI: 10.1128/iai.29.2.808-813.1980

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

Review 1.  Infections in cancer patients.

Authors:  G P Bodey
Journal:  Cancer Treat Rev       Date:  1975-06       Impact factor: 12.111

2.  Alimentary tract colonization by Candida albicans.

Authors:  H H Stone; C E Geheber; L D Kolb; W R Kitchens
Journal:  J Surg Res       Date:  1973-04       Impact factor: 2.192

3.  Inhibition of Candida albicans by Escherichia coli in vitro and in the germfree mouse.

Authors:  R P Hummel; E J Oestreicher; M P Maley; B G Macmillan
Journal:  J Surg Res       Date:  1973-07       Impact factor: 2.192

4.  Fungaemia and funguria after oral administration of Candida albicans.

Authors:  W Krause; H Matheis; K Wulf
Journal:  Lancet       Date:  1969-03-22       Impact factor: 79.321

5.  Studies in the pathogenesis, diagnosis, and treatment of Candida sepsis in children.

Authors:  H H Stone
Journal:  J Pediatr Surg       Date:  1974-02       Impact factor: 2.545

6.  Oral amphotericin for candidiasis in patients with hematologic neoplasms. An autopsy study.

Authors:  E Z Ezdinli; D D O'Sullivan; L P Wasser; U Kim; L Stutzman
Journal:  JAMA       Date:  1979-07-20       Impact factor: 56.272

7.  Gastrointestinal candidiasis in rats treated with antibiotics, cortisone, and azathioprine.

Authors:  A DeMaria; H Buckley; F von Lichtenberg
Journal:  Infect Immun       Date:  1976-06       Impact factor: 3.441

8.  Growth, morphogenesis, and virulence of Candida albicans after oral inoculation in the germ-free and conventional chick.

Authors:  E Balish; A W Phillips
Journal:  J Bacteriol       Date:  1966-05       Impact factor: 3.490

9.  Candida tropicalis: a major pathogen in immunocompromised patients.

Authors:  J R Wingard; W G Merz; R Saral
Journal:  Ann Intern Med       Date:  1979-10       Impact factor: 25.391

10.  Systemic candidiasis produced by oral Candida administration in mice.

Authors:  T Umenai
Journal:  Tohoku J Exp Med       Date:  1978-10       Impact factor: 1.848

View more
  23 in total

1.  Experimental gastrointestinal and disseminated candidiasis in immunocompromised animals.

Authors:  T J Walsh; P A Pizzo
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

Review 2.  Beyond Candida albicans: Mechanisms of immunity to non-albicans Candida species.

Authors:  Natasha Whibley; Sarah L Gaffen
Journal:  Cytokine       Date:  2015-08-11       Impact factor: 3.861

3.  Development of an orogastrointestinal mucosal model of candidiasis with dissemination to visceral organs.

Authors:  Karl V Clemons; Gloria M Gonzalez; Gaurav Singh; Jackie Imai; Marife Espiritu; Rachana Parmar; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

4.  Development of an integrative DNA transformation system for the yeast Candida tropicalis.

Authors:  L O Haas; J M Cregg; M A Gleeson
Journal:  J Bacteriol       Date:  1990-08       Impact factor: 3.490

5.  Effects of cyclophosphamide and ceftriaxone on gastrointestinal colonization of mice by Candida albicans.

Authors:  G Samonis; N C Karyotakis; E J Anaissie; E Barbounakis; S Maraki; Y Tselentis; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

6.  Ecology of Candida albicans gut colonization: inhibition of Candida adhesion, colonization, and dissemination from the gastrointestinal tract by bacterial antagonism.

Authors:  M J Kennedy; P A Volz
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

7.  Candida tropicalis infection in normal, diabetic, and neutropenic mice.

Authors:  R A Fromtling; G K Abruzzo; D M Giltinan
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

Review 8.  Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants.

Authors:  David Kaufman; Karen D Fairchild
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

9.  Gastric colonization with Candida albicans.

Authors:  R A Greenfield; W A Joyce
Journal:  Mycopathologia       Date:  1993-04       Impact factor: 2.574

10.  Evaluation of Abbott Quantum II yeast identification system.

Authors:  I F Salkin; K H Schadow; L A Bankaitis; M R McGinnis; M E Kemna
Journal:  J Clin Microbiol       Date:  1985-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.